Table 3.
Survey responses from 60 CTSAs with a focus on the source of emergency funding the institution received for COVID-19 research
| Source | Number of responses |
|---|---|
| Benefactors/donors | 16 |
| Institutional | 14 |
| Pharmaceutical/industry | 12 |
| State | 11 |
| Award supplements (i.e., NCATS) | 9 |
| NIH | 9 |
| Federal | 7 |
| Foundation grants | 7 |
| CARES act | 6 |
| Local CTSA | 5 |
| BARDA | 2 |
| DOD | 2 |
| HRSA | 2 |
COVID-19, The coronavirus disease 2019 AKA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease; BARDA, Biomedical Advanced Research and Development Authority; CTSA, Clinical and Translational Science Award; NCATS, National Center for Advancing Translational Sciences; CARES act, Coronavirus Aid, Relief, and Economic Security Act; NIH, National Institute of Health; DOD, Department of Defense; HRSA, Health Resources and Services Administration.